Established by long-time experienced business partners having previously launched and grown to M&A the firm Illumigen Biosciences, Kineta - formerly dba Lecura, Inc. - is organized around developing leading edge therapeutics in autoimmune disease, viral disease and chronic pain areas. A particular area of focus ihas been the discovery and development of antiviral therapies and immune modulating drugs for treatment of RNA viruses to include hepatitis C, influenza, west nile virus, and common cold. Employing a business model anchored in a broad range of collaborative efforts, the firm offers ShK Analogs for treatment of multiple sclerosis and autoimmune diseases; and RIG-I Pathway, a molecular on/off switch that triggers the human body's immune defenses against virus infection. In December 2022, Kineta completed its (reverse) merger with Yumanity Therapeutics, a move that had the effect of also making Kineta a public company (NASDA:KA). The combined company began trading Monday on the Nasdaq under the symbol KA and retains the Kineta name and leadership structure. Kineta also initiated enrollment in an early-stage clinical trial testing a candidate immunotherapy alone or in combination with Mercks Keytruda.
